Company: CERO
Filing Date: 2025-09-04
Form Type: 424B3
Source: 0001213900-25-084610
Chunk: 3

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-09-04
Form: 424B3
Chunk 3
---
 staff lack the discretion to grant the Company a cure period for demonstrating regaining compliance
with the Stockholders’ Equity Requirement. The Nasdaq staff indicated that the Company’s securities would be suspended from
trading on Nasdaq and delisted on September 8, 2025, subject to the Company’s right to appeal described below.

On September 3, 2025,
the Company requested a hearing to appeal such determination before a panel (the “Hearings Panel”). The hearing
request will stay the suspension of the trading of the Company’s common stock and delisting thereof pending such hearing or any
extension provided by the Hearings Panel.

At such hearing, the
Company intends to submit a plan to regain compliance with the Stockholders’ Equity Requirement. Such plan of compliance may include
the increase in stockholders’ equity through the consummation of public or private financing transactions.

No assurances can be
provided that the Company will consummate any financing transactions, obtain a favorable decision from the Hearings Panel or that the
Company will be able to regain or maintain compliance with Nasdaq listing’s rules.

<div align='center'>1

SIGNATURE</div>

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| CERO THERAPEUTICS HOLDINGS, INC. |                         |
| By:                              | /s/ Chris Ehrlich       |
| Name:                            | Chris Ehrlich           |
| Title:                           | Chief Executive Officer |

Dated: September 4, 2025

<div align='center'>2</div>